Clinical study on the effects of loteprednoletabonate 0.5%/Tobramycin 0.3% eyedrops after lamellar corneal refractive surgery

Hui Ding,Xingwu Zhong
DOI: https://doi.org/10.3760/cma.j.issn.1006-4443.2017.11.011
2017-01-01
Abstract:Objective To observe the effects of 0.5% loteprednoletabonate/0.3% tobramycin eye drops in lamellar refractive surgery patients.Methods This study enrolled 158 patients,77 cases (154 eyes) as treatment group and 81 cases (156 eyes) for control.Treatment group were treated with 0.5% loteprednoletabonate/0.3% tobramycin for 1 week,and control group with 0.1% dexamethasone/ 0.3% tobramycin.for 1 week.Results At 1 week post-surgery,the IOP 16.81±1.92 mmHg(M=17.425 mmHg)in treatment group was lower than 17.50±2.58mmHg (M=17.025 mmHg)for control(P =0.018).At 1 month,the IOP were 16.18±2.05rnmHg in treatment group and 16.34±2.28mmHg for control with no difference(P =0.83).Fluorescein staining and DLK were same (P >0.05).Conclusions 0.5% loteprednoletabonate/0.3% tobramycin.can inhibit inflammation and DLK with lower risk of IOP elevation than traditional steroids.
What problem does this paper attempt to address?